

Scott A Halperin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7432319/scott-a-halperin-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

377
papers

12,241
citations

55
h-index

91
g-index

397
ext. papers

13,803
ext. citations

5.1
avg. IF

6.21
L-index

#	Paper	IF	Citations
377	The effect of the COVID-19 pandemic on influenza-related hospitalization, intensive care admission and mortality in children in Canada: A population-based study.. <i>The Lancet Regional Health Americas</i> , 2022 , 7, 100132		0
376	Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network.. <i>Allergy, Asthma and Clinical Immunology</i> , 2022 , 18, 32	3.2	
375	Exploring the impact of media and information on self-reported intentions to vaccinate against COVID-19: A qualitative interview-based study.. <i>Human Vaccines and Immunotherapeutics</i> , 2022 , 1-9	4.4	0
374	The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.. <i>Vaccine</i> , 2021 , 40, 450-450	4.1	2
373	Is Conflict of interest Misnomer? Managing interests in immunization research and evaluation. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-6	4.4	1
372	Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial. <i>Vaccine</i> , 2021 , 39, 1598-1608	4.1	1
371	Obstetric and perinatal health outcomes after pertussis vaccination during pregnancy in Ontario, Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2021 , 9, E349	2.5	2
370	Health Outcomes in Young Children Following Pertussis Vaccination During Pregnancy. <i>Pediatrics</i> , 2021 , 147,	7.4	1
369	Public awareness, attitudes, beliefs, and behaviors regarding the role of pharmacists as immunizers. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 3052-3065	4.4	2
368	Tdap vaccination in pregnancy. <i>Cmaj</i> , 2021 , 193, E911	3.5	
367	The Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant Antibody Responses: Individual-Participant Data Meta-Analysis. <i>Frontiers in Immunology</i> , 2021 , 12, 689394	8.4	6
366	Identification of a Thiol-Disulfide Oxidoreductase (SdbA) Catalyzing Disulfide Bond Formation in the Superantigen SpeA in <i>Streptococcus pyogenes</i> . <i>Journal of Bacteriology</i> , 2021 , 203, e0015321	3.5	1
365	Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis. <i>Vaccine</i> , 2021 , 39, 6545-6552	4.1	2
364	Review of pediatric encephalitis and encephalopathy cases following immunization reported to the Canadian Immunization Monitoring Program Active (IMPACT) from 1992 to 2012. <i>Vaccine</i> , 2020 , 38, 4457-4463	4.4	2
363	Pharmacists as immunizers to Improve coverage and provider/recipient satisfaction: A prospective, Controlled Community Embedded Study with vaccines with low coverage rates (the Improve ACCESS Study): Study summary and anticipated significance. <i>Canadian Pharmacists Journal</i> , 2020 , 153, 88-94	1.3	2
362	COVID-19 in children: the link in the transmission chain. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 633-634	15.5	159
361	Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada. <i>Emerging Infectious Diseases</i> , 2020 , 26, 454-462	10.2	

360	Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, e439-e448	11.6	3
359	Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). <i>Vaccine</i> , 2020 , 38, 2026-2033	4.1	2
358	Vaccination during pregnancy: Canadian maternity care providers' opinions and practices. <i>Human Vaccines and Immunotherapeutics</i> , 2020 , 16, 2789-2799	4.4	1
357	Implementation Effectiveness of a Parent-Directed YouTube Video ("It Doesn't Have To Hurt") on Evidence-Based Strategies to Manage Needle Pain: Descriptive Survey Study. <i>JMIR Pediatrics and Parenting</i> , 2020 , 3, e13552	4.2	7
356	Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia. <i>Eurosurveillance</i> , 2020 , 25,	19.8	4
355	Pertussis vaccination in pregnancy in Canada: a cost-utility analysis. <i>CMAJ Open</i> , 2020 , 8, E651-E658	2.5	1
354	Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults. <i>Journal of Medical Microbiology</i> , 2020 , 69, 256-264	3.2	4
353	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. <i>Vaccine</i> , 2020 , 38, 1384-1392	4.1	21
352	Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. <i>Vaccine</i> , 2020 , 38, 2105-2114	4.1	10
351	Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. <i>Vaccine</i> , 2020 , 38, 2095-2104	4.1	10
350	Indigenous Peoples, settler colonialism, and access to health care in rural and northern Ontario. <i>Health and Place</i> , 2020 , 66, 102445	4.6	3
349	Assessing the completeness of infant and childhood immunizations within a provincial registry populated by parental reporting: A study using linked databases in Ontario, Canada. <i>Vaccine</i> , 2020 , 38, 5223-5230	4.1	2
348	A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age. <i>Vaccines</i> , 2020 , 8,	5.3	5
347	Burden of Children Hospitalized With Pertussis in Canada in the Acellular Pertussis Vaccine Era, 1999-2015. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020 , 9, 118-127	4.8	18
346	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , 2019 , 155, 69-78	5.3	36
345	Effect of alcohol skin cleansing on vaccination-associated infections and local skin reactions: a randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 995-1002	4.4	3
344	Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial. <i>Vaccine</i> , 2019 , 37, 289-295	4.1	4
343	Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 2856-2864	4.4	4

342	Identification of Redox Partners of the Thiol-Disulfide Oxidoreductase SdbA in <i>Streptococcus gordonii</i> . <i>Journal of Bacteriology</i> , 2019 , 201,	3.5	2
341	Immunogenicity, Lot Consistency, and Extended Safety of rVSV-G-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1127-1135	7	23
340	Measles Antibody Levels in Young Infants. <i>Pediatrics</i> , 2019 , 144,	7.4	13
339	Vaccination Against Influenza in Pregnancy: A Survey of Canadian Maternity Care Providers. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019 , 41, 479-488	1.3	13
338	Knowledge, attitudes, behaviours, and beliefs of healthcare provider students regarding mandatory influenza vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 700-709	4.4	12
337	Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019 , 8, 105-114	4.8	9
336	Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. <i>Vaccine</i> , 2018 , 36, 1908-1916	4.1	14
335	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. <i>Journal of Infectious Diseases</i> , 2018 , 218, 378-387	7	27
334	Waning of measles maternal antibody in infants in measles elimination settings - A systematic literature review. <i>Vaccine</i> , 2018 , 36, 1248-1255	4.1	25
333	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). <i>Vaccine</i> , 2018 , 36, 2166-2175	4.1	39
332	Expression, purification, and functional analysis of an antigen-targeting fusion protein composed of CD40 ligand and the C-terminal fragment of ovalbumin. <i>Protein Expression and Purification</i> , 2018 , 142, 37-44	2	4
331	Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 59-66	4.4	4
330	A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1063-1071	11.6	56
329	Contact among healthcare workers in the hospital setting: developing the evidence base for innovative approaches to infection control. <i>BMC Infectious Diseases</i> , 2018 , 18, 184	4	9
328	Invasive <i>Haemophilus Influenzae</i> Type B Infections in Children with Cancer in the Era of Infant Hib Immunization Programs (1991-2014): A Report From the Canadian Immunization Monitoring Program Active. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 726-728	3.4	3
327	Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 1220-1230	11.5	24
326	Functional activity of maternal and cord antibodies elicited by an investigational group B <i>Streptococcus</i> trivalent glycoconjugate vaccine in pregnant women. <i>Journal of Infection</i> , 2018 , 76, 449-456	18.9	12
325	Pertussis and influenza immunisation during pregnancy: a landscape review. <i>Lancet Infectious Diseases</i> , 2017 , 17, e209-e222	25.5	64

324	Maternal immunisation: collaborating with mother nature. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, e197-e208	2.5	92
323	Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. <i>Cmaj</i> , 2017 , 189, E819-E827	3.5	53
322	Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 2048-2057	4.4	20
321	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2017 , 215, 1789-1798	7	53
320	Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination program. <i>Vaccine</i> , 2017 , 35, 2520-2530	4.1	17
319	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. <i>BMC Infectious Diseases</i> , 2017 , 17, 805	4	14
318	Assessing the risk of intussusception and rotavirus vaccine safety in Canada. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 703-710	4.4	14
317	A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. <i>Journal of Infectious Diseases</i> , 2017 , 215, 24-33	7	37
316	Case-control study of household contacts to examine immunological protection from transmission - study protocol. <i>CMAJ Open</i> , 2017 , 5, E872-E877	2.5	1
315	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. <i>Journal of Infectious Diseases</i> , 2017 , 216, 405-414	7	83
314	Knowledge, attitudes, beliefs, and behaviors of parents and healthcare providers before and after implementation of a universal rotavirus vaccination program. <i>Vaccine</i> , 2016 , 34, 687-695	4.1	9
313	Thiol-Disulfide Exchange in Gram-Positive Firmicutes. <i>Trends in Microbiology</i> , 2016 , 24, 902-915	12.4	24
312	Hospitalization for Influenza A Versus B. <i>Pediatrics</i> , 2016 , 138,	7.4	51
311	Respiratory macrophages regulate CD4 T memory responses to mucosal immunization with recombinant adenovirus-based vaccines. <i>Cellular Immunology</i> , 2016 , 310, 53-62	4.4	4
310	Do Dose Numbers Matter?: Evaluation of Differing Infant and Toddler Meningococcal C Conjugate Vaccine Programs in Canadian Children. <i>Pediatric Infectious Disease Journal</i> , 2016 , 35, 1242-1246	3.4	1
309	Immunizing Patients With Adverse Events After Immunization and Potential Contraindications to Immunization: A Report From the Special Immunization Clinics Network. <i>Pediatric Infectious Disease Journal</i> , 2016 , 35, e384-e391	3.4	7
308	Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study. <i>Vaccine</i> , 2016 , 34, 4046-9	4.1	18
307	Exposure-based Interventions for the management of individuals with high levels of needle fear across the lifespan: a clinical practice guideline and call for further research. <i>Cognitive Behaviour Therapy</i> , 2016 , 45, 217-35	4.4	42

306	Knowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 879-85	4.4	21
305	Routine immunization of adults by pharmacists: Attitudes and beliefs of the Canadian public and health care providers. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 623-31	4.4	28
304	Mutation of the Thiol-Disulfide Oxidoreductase SdbA Activates the CiaRH Two-Component System, Leading to Bacteriocin Expression Shutdown in <i>Streptococcus gordonii</i> . <i>Journal of Bacteriology</i> , 2016 , 198, 321-31	3.5	7
303	Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial. <i>Obstetrics and Gynecology</i> , 2016 , 127, 213-21	4.9	58
302	Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 931-6	4.4	8
301	Improving rates of maternal immunization: Challenges and opportunities. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 857-65	4.4	48
300	Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network. <i>PLoS ONE</i> , 2016 , 11, e0156118	3.7	76
299	Immunization in Canada: Update for 2015. <i>Journal of the Canadian Chiropractic Association</i> , 2016 , 60, 6-12	0.6	
298	New Challenges for Pertussis Vaccines 2016 , 205-221		
297	Mutation of the <i>Streptococcus gordonii</i> Thiol-Disulfide Oxidoreductase SdbA Leads to Enhanced Biofilm Formation Mediated by the CiaRH Two-Component Signaling System. <i>PLoS ONE</i> , 2016 , 11, e0166656	3.7	10
296	The disulfide oxidoreductase SdbA is active in <i>Streptococcus gordonii</i> using a single C-terminal cysteine of the CXXC motif. <i>Molecular Microbiology</i> , 2016 , 99, 236-53	4.1	8
295	Development of a gene delivery system in <i>Streptococcus gordonii</i> using thymidylate synthase as a selection marker. <i>Journal of Microbiological Methods</i> , 2016 , 125, 43-8	2.8	2
294	The role of healthcare provider attitudes in increasing willingness to accept seasonal influenza vaccine policy changes. <i>Vaccine</i> , 2016 , 34, 5704-5707	4.1	2
293	Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. <i>Clinical Infectious Diseases</i> , 2015 , 60, e27-35	11.6	50
292	Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 2167-79	4.4	12
291	A universal infant rotavirus vaccine program in two delivery models: Effectiveness and adverse events following immunization. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 870-4	4.4	7
290	Against vaccine assay secrecy. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 498-503	4.4	1
289	Reducing pain during vaccine injections: clinical practice guideline. <i>Cmaj</i> , 2015 , 187, 975-982	3.5	143

288	CD43-, but not CD43+, IL-10-producing CD1dhiCD5+ B cells suppress type 1 immune responses during <i>Chlamydia muridarum</i> genital tract infection. <i>Mucosal Immunology</i> , 2015 , 8, 94-106	9.2	15
287	Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. <i>Vaccine</i> , 2015 , 33, 6635-40 ^{4.1}	4.1	8
286	Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What the Canadian public knows and wants to know. <i>Vaccine</i> , 2015 , 33, 6840-8	4.1	7
285	The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. <i>BMJ Open</i> , 2015 , 5, e009062	3	45
284	Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. <i>Pediatric Infectious Disease Journal</i> , 2015 , 34, e222-32	3.4	152
283	Guillain-Barré Syndrome After Immunization in Canadian Children (1996-2012). <i>Pediatric Infectious Disease Journal</i> , 2015 , 34, 1411-3	3.4	5
282	Immunoblotting conditions for small peptides from streptococci. <i>Journal of Microbiological Methods</i> , 2015 , 114, 40-2	2.8	3
281	Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015 , 4, 242-51	4.8	25
280	Pharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults: Systematic Review and Meta-Analysis. <i>Clinical Journal of Pain</i> , 2015 , 31, S38-63	3.5	65
279	Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial. <i>Vaccine</i> , 2015 , 33, 559-67	4.1	13
278	<i>Bordetella pertussis</i> 2015 , 2619-2628.e3		3
277	Canadian vaccine research networks: Vaccine safety resources for Canada. <i>Canada Communicable Disease Report</i> , 2015 , 41, 18-23	3.1	1
276	Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women. <i>Vaccine</i> , 2014 , 32, 6493-8	4.1	6
275	Acellular vaccines for preventing whooping cough in children. <i>The Cochrane Library</i> , 2014 , CD001478	5.2	52
274	High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. <i>Journal of Clinical Immunology</i> , 2014 , 34, 655-62	5.7	6
273	Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. <i>BMC Public Health</i> , 2014 , 14, 442	4.1	42
272	Approved but non-funded vaccines: accessing individual protection. <i>Vaccine</i> , 2014 , 32, 766-70	4.1	13
271	Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines. <i>Vaccine</i> , 2014 , 32, 3336-40	4.1	12

270	Childhood immunization rates in Canada are too low: UNICEF. <i>Paediatrics and Child Health</i> , 2014 , 19, 237-87	0.7	9
269	Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network. <i>Paediatrics and Child Health</i> , 2014 , 19, 310-314	0.7	7
268	Implementation of a universal rotavirus vaccination program: comparison of two delivery systems. <i>BMC Public Health</i> , 2014 , 14, 908	4.1	8
267	Nonhuman primate and human challenge models of pertussis. <i>Journal of Infectious Diseases</i> , 2014 , 209 Suppl 1, S20-3	7	28
266	The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1208-15	11.6	35
265	Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. <i>Journal of the Pediatric Infectious Disease Society</i> , 2014 , 9, 93-102	4.8	19
264	Burden of seasonal influenza in children with neurodevelopmental conditions. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 710-4	3.4	23
263	Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 73-80	3.4	18
262	Maintaining the momentum: key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 3629-41	4.4	12
261	The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases. <i>Canada Communicable Disease Report</i> , 2014 , 40, 41-44	3.1	8
260	Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network. <i>Paediatrics and Child Health</i> , 2014 , 19, 310-4	0.7	3
259	Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. <i>Vaccine</i> , 2013 , 31, 3148-55	4.1	32
258	Controlling serogroup B invasive meningococcal disease: the Canadian perspective. <i>Expert Review of Vaccines</i> , 2013 , 12, 505-17	5.2	15
257	Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. <i>International Journal of STD and AIDS</i> , 2013 , 24, 345-9	1.4	8
256	Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). <i>Vaccine</i> , 2013 , 32, 124-30	4.1	73
255	Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada. <i>Vaccine</i> , 2013 , 31, 5700-5	4.1	4
254	CD4+CD25+Foxp3+ regulatory T cells promote Th17 responses and genital tract inflammation upon intracellular Chlamydia muridarum infection. <i>Journal of Immunology</i> , 2013 , 191, 3430-9	5.3	34
253	Response to the changing epidemiology of meningococcal disease in North America 1945-2010. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 1323-4	4.4	2

252	Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. <i>Journal of Infectious Diseases</i> , 2013 , 208, 544-53	7	53
251	Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study. <i>Vaccine Journal</i> , 2013 , 20, 1108-14		8
250	Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1793-802	27.4	284
249	Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. <i>Vaccine Journal</i> , 2013 , 20, 459-67		14
248	Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 1438-44	4.4	17
247	Functional analysis of paralogous thiol-disulfide oxidoreductases in <i>Streptococcus gordonii</i> . <i>Journal of Biological Chemistry</i> , 2013 , 288, 16416-16429	5.4	16
246	Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 2460-73	4.4	37
245	Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 136-43	4.4	5
244	Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. <i>Pediatric Infectious Disease Journal</i> , 2013 , 32, 54-61	3.4	19
243	The disease burden of invasive meningococcal serogroup B disease in Canada. <i>Pediatric Infectious Disease Journal</i> , 2013 , 32, e20-5	3.4	46
242	Influenza immunization practices and policies for health care students in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013 , 24, 195-201	2.6	3
241	Acellular vaccines for preventing whooping cough in children. <i>Cochrane Database of Systematic Reviews</i> , 2012 , CD001478		23
240	A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. <i>Vaccine</i> , 2012 , 30, 6287-93	4.1	23
239	Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital <i>Chlamydia muridarum</i> infection. <i>Vaccine</i> , 2012 , 30, 350-60	4.1	21
238	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. <i>Vaccine</i> , 2012 , 30, 974-82	4.1	37
237	The changing and dynamic epidemiology of meningococcal disease. <i>Vaccine</i> , 2012 , 30 Suppl 2, B26-36	4.1	220
236	The challenge of post-implementation surveillance for novel meningococcal vaccines. <i>Vaccine</i> , 2012 , 30 Suppl 2, B67-72	4.1	23
235	Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. <i>Vaccine</i> , 2012 , 30, 2556-63	4.1	86

234	Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. <i>Vaccine</i> , 2012 , 30, 2831-8	4.1	27
233	Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. <i>Vaccine</i> , 2012 , 30, 3389-94	4.1	14
232	Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2012 , 30, 4558-77	4.1	23
231	Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis. <i>Vaccine</i> , 2012 , 30, 4023-7	4.1	8
230	Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. <i>Vaccine</i> , 2012 , 30, 5445-8	4.1	28
229	A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. <i>BMC Infectious Diseases</i> , 2012 , 12, 279	4	14
228	Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals. <i>BMC Infectious Diseases</i> , 2012 , 12, 306	4	11
227	Challenges to immunization: the experiences of homeless youth. <i>BMC Public Health</i> , 2012 , 12, 338	4.1	10
226	Cost effectiveness of infant vaccination for rotavirus in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012 , 23, 71-7	2.6	22
225	Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 591-7	5.3	1
224	Human challenge studies: a review of adequacy of reporting methods and results. <i>Future Microbiology</i> , 2012 , 7, 481-95	2.9	11
223	Role of surface proteins SspA and SspB of <i>Streptococcus gordonii</i> in innate immunity. <i>Microbiology (United Kingdom)</i> , 2012 , 158, 2099-2106	2.9	12
222	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N12009 and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012 , 13, 23-32		21
221	Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009. <i>Pediatrics</i> , 2012 , 130, 397-406	7.4	28
220	The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 956-63	3.4	37
219	Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 72-7	3.4	45
218	The hidden costs and characteristics of childhood rotavirus emergency visits in Canada. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 159-63	3.4	8
217	Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 188-93	3.4	6

216	High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. <i>HIV Clinical Trials</i> , 2012 , 13, 23-32		11
215	Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. <i>Vaccine</i> , 2011 , 29, 1324-31	4.1	11
214	Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. <i>Vaccine</i> , 2011 , 29, 1595-604	4.1	44
213	Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. <i>Vaccine</i> , 2011 , 29, 6540-8	4.1	50
212	Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. <i>Vaccine</i> , 2011 , 29, 8459-65	4.1	33
211	Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets. <i>Vaccine</i> , 2011 , 29, 7718-26	4.1	29
210	Optimizing Canadian public immunization programs: a prescription for action. <i>Canadian Journal of Public Health</i> , 2011 , 102, 193-5	3.2	1
209	Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillance. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011 , 22, 15-8	2.6	9
208	Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 402-7	3.4	22
207	Acellular vaccines for preventing whooping cough in children. <i>Cochrane Database of Systematic Reviews</i> , 2011 , CD001478		14
206	Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. <i>Pediatrics</i> , 2011 , 128, e276-89	7.4	51
205	The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. <i>Cmaj</i> , 2011 , 183, E1033-7	3.5	13
204	Hospital acquired rotavirus infections: burden in Canadian paediatric hospitals. <i>Journal of Infection Prevention</i> , 2011 , 12, 159-162	1.1	6
203	Strategies for successful rapid trials of influenza vaccine. <i>Clinical Trials</i> , 2011 , 8, 699-704	2.2	6
202	Role of the cell wall microenvironment in expression of a heterologous SpaP-S1 fusion protein by <i>Streptococcus gordonii</i> . <i>Applied and Environmental Microbiology</i> , 2011 , 77, 1660-6	4.8	10
201	Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. <i>Clinical Infectious Diseases</i> , 2011 , 53, 885-92	11.6	113
200	Regulation of D-alanylation of lipoteichoic acid in <i>Streptococcus gordonii</i> . <i>Microbiology (United Kingdom)</i> , 2011 , 157, 2248-2256	2.9	14
199	Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. <i>PLoS ONE</i> , 2011 , 6, e17758	3.7	35

198	Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline. <i>Cmaj</i> , 2010 , 182, E843-55	3.5	136
197	Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline (summary). <i>Cmaj</i> , 2010 , 182, 1989-95	3.5	103
196	The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. <i>Vaccine</i> , 2010 , 28, 2130-6	4.1	79
195	Pertussis immunization in paediatric healthcare workers: knowledge, attitudes, beliefs, and behaviour. <i>Vaccine</i> , 2010 , 28, 2169-2173	4.1	16
194	Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases. <i>Vaccine</i> , 2010 , 28, 3180-4	4.1	52
193	Regrettable lack of definition of the "well tolerated" vaccine. <i>Vaccine</i> , 2010 , 28, 3755-6	4.1	
192	The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. <i>Vaccine</i> , 2010 , 28, 8001-7	4.1	66
191	Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. <i>Vaccine</i> , 2010 , 28, 7865-72	4.1	45
190	Hepatitis A and travel amongst Nova Scotia postsecondary students: evidence for a targeted vs. universal immunization strategy. <i>Vaccine</i> , 2010 , 28, 8105-11	4.1	7
189	Substantial morbidity for hospitalized children with community-acquired rotavirus infections: 2005-2007 IMPACT surveillance in Canadian hospitals. <i>Pediatric Infectious Disease Journal</i> , 2010 , 29, 879-82	3.4	34
188	Haemophilus Disease in Alaskan and Canadian Children. <i>Pediatric Infectious Disease Journal</i> , 2010 , 29, 186-187	3.4	
187	Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010 , 29, 259-67	5.3	35
186	Immunization in Canada: a 6-year update. <i>Journal of the Canadian Chiropractic Association</i> , 2010 , 54, 85-90	6	3
185	<i>Bordetella pertussis</i> 2010 , 2955-2964		5
184	Postvaccination thrombocytopenia in Canada. <i>Pediatric Infectious Disease Journal</i> , 2010 , 29, 559-61	3.4	15
183	Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009 , 20, e130-4	2.6	16
182	Overcoming codon-usage bias in heterologous protein expression in <i>Streptococcus gordonii</i> . <i>Microbiology (United Kingdom)</i> , 2009 , 155, 3581-3588	2.9	10
181	Critical role of the interleukin-17/interleukin-17 receptor axis in regulating host susceptibility to respiratory infection with <i>Chlamydia</i> species. <i>Infection and Immunity</i> , 2009 , 77, 5059-70	3.7	55

180	Expression of the Streptococcus mutans essential two-component regulatory system VicRK is pH and growth-phase dependent and controlled by the LiaFSR three-component regulatory system. <i>Microbiology (United Kingdom)</i> , 2009 , 155, 2856-2865	2.9	39
179	Inadequate pain management during routine childhood immunizations: the nerve of it. <i>Clinical Therapeutics</i> , 2009 , 31 Suppl 2, S152-67	3.5	163
178	Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii. <i>Scandinavian Journal of Immunology</i> , 2009 , 69, 351-6	3.4	27
177	Pediatric combined formulation DTaP-IPV/Hib vaccine. <i>Expert Review of Vaccines</i> , 2009 , 8, 831-40	5.2	16
176	Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. <i>Vaccine</i> , 2009 , 27, 2540-7	4.1	18
175	Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. <i>Vaccine</i> , 2009 , 27, 2701-6	4.1	21
174	A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. <i>Vaccine</i> , 2009 , 27, 4662-71	4.1	67
173	Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor. <i>Molecular Immunology</i> , 2009 , 46, 1883-91	4.3	15
172	Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). <i>Expert Review of Vaccines</i> , 2009 , 8, 679-88	5.2	103
171	The yin and yang of paracetamol and paediatric immunisations. <i>Lancet, The</i> , 2009 , 374, 1305-6	4.0	11
170	Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 186-93	3.4	55
169	Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 582-7	3.4	51
168	Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. <i>Pediatric Infectious Disease Journal</i>	3.4	30
167	Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 985-9	3.4	15
166	What is the Significance of a High Cycle Threshold Positive IS481 PCR for Bordetella pertussis?. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 1143-1144	3.4	
165	Immunization in pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009 , 31, 1085-101	1.3	29
164	Immunisation pendant la grossesse. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009 , 31, 1093-1101	1.3	1
163	The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 220-4	3.4	64

162	Pertussis 2009 , 577-595		2
161	A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2008 , 26, 6800-13	4.1	42
160	Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 173-84	27.4	175
159	Expression of a functional single-chain variable-fragment antibody against complement receptor 1 in <i>Streptococcus gordonii</i> . <i>Vaccine Journal</i> , 2008 , 15, 925-31		13
158	Immunization in pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2008 , 30, 1149-54	1.3	5
157	Ongoing control of <i>Haemophilus influenzae</i> type B infections in Canadian children, 2004-2007. <i>Pediatric Infectious Disease Journal</i> , 2008 , 27, 755-7	3.4	16
156	A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008 , 19, 419-23	2.6	11
155	The epidemiology of children hospitalized with herpes zoster in Canada: Immunization Monitoring Program, Active (IMPACT), 1991-2005. <i>Pediatric Infectious Disease Journal</i> , 2008 , 27, 112-8	3.4	14
154	The challenges facing Canadian trialists in an increasingly competitive global market: What can be done to remain competitive?. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007 , 18, 205-8	2.6	1
153	Invasive pneumococcal infections in Canadian children, 1998-2003: implications for new vaccination programs. <i>Canadian Journal of Public Health</i> , 2007 , 98, 111-5	3.2	9
152	Role of D-alanylation of <i>Streptococcus gordonii</i> lipoteichoic acid in innate and adaptive immunity. <i>Infection and Immunity</i> , 2007 , 75, 3033-42	3.7	37
151	The control of pertussis--2007 and beyond. <i>New England Journal of Medicine</i> , 2007 , 356, 110-3	59.2	98
150	Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model. <i>Vaccine Journal</i> , 2007 , 14, 1381-3		8
149	Construction and characterization of single-chain variable fragment antibodies directed against the <i>Bordetella pertussis</i> surface adhesins filamentous hemagglutinin and pertactin. <i>Infection and Immunity</i> , 2007 , 75, 5476-82	3.7	9
148	Invasive infections caused by <i>haemophilus influenzae</i> serotypes in twelve Canadian IMPACT centers, 1996-2001. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 1025-31	3.4	58
147	Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young children. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 387-92	3.4	3
146	The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 31-5	3.4	42
145	Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 79-81	3.4	35

144	Transmission of <i>Bordetella pertussis</i> to young infants. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 293-94	3.4	337
143	Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. <i>Vaccine</i> , 2007 , 25, 450-7	4.1	36
142	An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. <i>Vaccine</i> , 2007 , 25, 1121-5	4.1	22
141	Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. <i>Vaccine</i> , 2007 , 25, 3464-74	4.1	21
140	Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. <i>Vaccine</i> , 2007 , 25, 5858-74	4.1	28
139	Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2007 , 25, 5821-38	4.1	12
138	Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2007 , 25, 5803-20	4.1	11
137	Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. <i>Vaccine</i> , 2007 , 25, 5875-81	4.1	27
136	Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2007 , 25, 5839-57	4.1	18
135	Expression and purification of a trivalent pertussis toxin-diphtheria toxin-tetanus toxin fusion protein in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2007 , 51, 170-8	2	8
134	Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL and ADACEL. <i>Expert Opinion on Biological Therapy</i> , 2006 , 6, 807-21	5.4	8
133	Has the change to acellular pertussis vaccine improved or worsened pertussis control?. <i>Cmaj</i> , 2006 , 175, 1227	3.5	2
132	Surveillance for influenza admissions among children hospitalized in Canadian immunization monitoring program active centers, 2003-2004. <i>Pediatrics</i> , 2006 , 118, e610-9	7.4	67
131	Expression of a pertussis toxin S1 fragment by inducible promoters in oral <i>Streptococcus</i> and the induction of immune responses during oral colonization in mice. <i>Canadian Journal of Microbiology</i> , 2006 , 52, 436-44	3.2	8
130	Reduced-Antigen, Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine, Adsorbed (Boostrix [®] US Formulation). <i>Paediatric Drugs</i> , 2006 , 8, 196	4.2	
129	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. <i>International Congress Series</i> , 2006 , 1289, 303-306		11
128	Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future. <i>Journal of Pediatrics</i> , 2006 , 149, 589-91	3.6	8
127	Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. <i>Vaccine</i> , 2006 , 24, 20-6	4.1	99

126	Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults. <i>Vaccine</i> , 2006 , 24, 1601-8	4.1	28
125	Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. <i>Vaccine</i> , 2006 , 24, 4017-23	4.1	11
124	Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP/IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. <i>Vaccine</i> , 2006 , 24, 2057-64	4.1	32
123	Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005. <i>Paediatrics and Child Health</i> , 2006 , 11, 413-415	0.7	
122	Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2006 , 17, 224-8	2.6	1
121	How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. <i>Pediatric Infectious Disease Journal</i> , 2006 , 25, 195-200	3.4	70
120	The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. <i>Pediatric Infectious Disease Journal</i> , 2006 , 25, 615-22	3.4	45
119	Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. <i>Clinical and Experimental Immunology</i> , 2006 , 144, 543-51	6.2	23
118	Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005. <i>Paediatrics and Child Health</i> , 2006 , 11, 413-5	0.7	
117	Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age. <i>Hum Vaccin</i> , 2005 , 1, 180-6		14
116	Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. <i>Hum Vaccin</i> , 2005 , 1, 140-2		7
115	Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. <i>Pediatric Infectious Disease Journal</i> , 2005 , 24, S83-6	3.4	30
114	Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. <i>Hum Vaccin</i> , 2005 , 1, 37-42		17
113	Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1114-22	11.6	232
112	Expression of diphtheria toxin in Streptococcus mutans and induction of toxin-neutralizing antisera. <i>Canadian Journal of Microbiology</i> , 2005 , 51, 841-6	3.2	2
111	Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. <i>Pediatric Infectious Disease Journal</i> , 2005 , 24, 481-8	3.4	86
110	Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. <i>Pediatric Infectious Disease Journal</i> , 2005 , 24, S141-6	3.4	33
109	Group B streptococcal testing during pregnancy: survey of postpartum women and audit of current prenatal screening practices. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2005 , 27, 1006-12	1.3	5

108	A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. <i>Pediatric Infectious Disease Journal</i> , 2005 , 24, 1059-66	3.4	43
107	Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. <i>Hum Vaccin</i> , 2005 , 1, 245-50		14
106	Infection of newborn piglets with Bordetella pertussis: a new model for pertussis. <i>Infection and Immunity</i> , 2005 , 73, 3636-45	3.7	48
105	Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. <i>Cmaj</i> , 2005 , 172, 53-6	3.5	37
104	Conforming to ICMJE principles. <i>Cmaj</i> , 2005 , 173, 1358-9	3.5	4
103	Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. <i>Pediatrics</i> , 2004 , 114, e96-101	7.4	83
102	Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 5364-7	9.7	58
101	Expression and immunogenicity of a recombinant diphtheria toxin fragment A in Streptococcus gordonii. <i>Applied and Environmental Microbiology</i> , 2004 , 70, 4569-74	4.8	15
100	Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. <i>Vaccine</i> , 2004 , 22, 575-85	4.1	31
99	Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. <i>Vaccine</i> , 2004 , 22, 586-91	4.1	12
98	Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. <i>Vaccine</i> , 2004 , 22, 563-8	4.1	18
97	Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. <i>Pediatric Infectious Disease Journal</i> , 2004 , 23, 568-71	3.4	36
96	Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. <i>Infection and Immunity</i> , 2003 , 71, 2272-5	3.7	30
95	. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 119-122	3.4	5
94	Thrombocytopenia after immunization of Canadian children, 1992 to 2001. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 119-22	3.4	44
93	CanadaQ first universal varicella immunization program: Lessons from Prince Edward Island. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2003 , 14, 41-4		8
92	Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. <i>Pediatrics</i> , 2003 , 112, e348	7.4	70
91	A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. <i>Vaccine</i> , 2003 , 21, 2461-7	4.1	193

90	Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. <i>Vaccine</i> , 2003 , 21, 2298-306	4.1	36
89	A pilot study to quantify parental anxiety associated with enrollment of an infant or toddler in a phase III vaccine trial. <i>Vaccine</i> , 2003 , 21, 3863-6	4.1	4
88	Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. <i>Journal of Pediatrics</i> , 2003 , 143, 576-81	3.6	129
87	Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. <i>Seminars in Pediatric Infectious Diseases</i> , 2003 , 14, 213-9		44
86	Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. <i>Clinical Infectious Diseases</i> , 2003 , 36, e1-4	11.6	32
85	Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. <i>Pediatrics</i> , 2003 , 112, e453	7.4	33
84	Pertussis control in Canada. <i>Cmaj</i> , 2003 , 168, 1389-90	3.5	
83	Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial. <i>Cmaj</i> , 2003 , 169, 111-7	3.5	10
82	Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. <i>Paediatrics and Child Health</i> , 2002 , 7, 645-648	0.7	6
81	Compliance with recommendations for routine HIV screening during pregnancy in Halifax. <i>Paediatrics and Child Health</i> , 2002 , 7, 81-4	0.7	1
80	Allergy to antibiotics in children: Perception versus reality. <i>Paediatrics and Child Health</i> , 2002 , 7, 233-7	0.7	2
79	Three-year follow-up of protection rates in children given varicella vaccine. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2002 , 13, 382-6		19
78	Oral colonization and immune responses to <i>Streptococcus gordonii</i> expressing a pertussis toxin S1 fragment in mice. <i>FEMS Microbiology Letters</i> , 2002 , 208, 175-8	2.9	33
77	Purification and immunogenicity of a recombinant <i>Bordetella pertussis</i> S1S3FHA fusion protein expressed by <i>Streptococcus gordonii</i> . <i>Applied and Environmental Microbiology</i> , 2002 , 68, 4253-8	4.8	23
76	The changing age and seasonal profile of pertussis in Canada. <i>Journal of Infectious Diseases</i> , 2002 , 185, 1448-53	7	180
75	Outcome of penicillin-nonsusceptible <i>Streptococcus pneumoniae</i> meningitis: a nested case-control study. <i>Pediatric Infectious Disease Journal</i> , 2002 , 21, 903-10	3.4	34
74	Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. <i>Pediatric Infectious Disease Journal</i> , 2002 , 21, 399-405	3.4	38
73	Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. <i>Pediatric Infectious Disease Journal</i> , 2002 , 21, 947-50	3.4	19

72	Pertussis of adults and infants. <i>Lancet Infectious Diseases, The</i> , 2002 , 2, 744-50	25.5	338
71	Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. <i>Vaccine</i> , 2002 , 20, 1240-7	4.1	77
70	Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. <i>Paediatrics and Child Health</i> , 2002 , 7, 645-8	0.7	2
69	Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. <i>Clinical and Investigative Medicine</i> , 2002 , 25, 243-51	0.9	10
68	Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. <i>Clinical Infectious Diseases</i> , 2001 , 32, 1691-7	11.6	196
67	Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. <i>Vaccine</i> , 2001 , 19, 4720-6	4.1	46
66	Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine. <i>Vaccine</i> , 2001 , 19, 3004-8	4.1	7
65	Pertussis immunization for adolescents: What are we waiting for?. <i>Paediatrics and Child Health</i> , 2001 , 6, 184-6	0.7	4
64	Pertussis immunization for adolescents: What are we waiting for?. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001 , 12, 74-6		3
63	Gemella species endocarditis in a child. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001 , 12, 317-20		6
62	Reduced susceptibility to penicillin among pneumococci causing invasive infection in children - Canada, 1991 to 1998. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001 , 12, 241-6		8
61	Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. <i>Pediatric Infectious Disease Journal</i> , 2000 , 19, 276-83	3.4	68
60	Lyme disease vaccine. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2000 , 11, 132-4		
59	Reactogenicity to a live attenuated varicella vaccine in Canadian children. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2000 , 11, 97-101		12
58	Lyme disease vaccine. <i>Paediatrics and Child Health</i> , 2000 , 5, 203-5	0.7	
57	Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). <i>Clinical Infectious Diseases</i> , 2000 , 31, 58-64	11.6	84
56	Morbidity of pertussis in adolescents and adults. <i>Journal of Infectious Diseases</i> , 2000 , 182, 174-9	7	250
55	An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. <i>Vaccine</i> , 2000 , 18, 1312-9	4.1	78

54	Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. <i>Journal of Pediatrics</i> , 2000 , 136, 789-794	3.6	52
53	Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. <i>Journal of Pediatrics</i> , 2000 , 136, 0789-0794	3.6	11
52	The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. <i>Pediatric Infectious Disease Journal</i> , 2000 , 19, 1053-9	3.4	33
51	Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 283, 1826-7	27.4	33
50	Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. <i>Journal of Pediatrics</i> , 2000 , 136, 789-94	3.6	12
49	A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. <i>Pediatrics</i> , 1999 , 104, e42	7.4	46
48	Failure of physicians to consider the diagnosis of pertussis in children. <i>Clinical Infectious Diseases</i> , 1999 , 28, 840-6	11.6	57
47	Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. <i>Clinical Infectious Diseases</i> , 1999 , 28, 995-1001	11.6	54
46	Developing better paediatric vaccines: the case of pertussis vaccine. <i>BioDrugs</i> , 1999 , 12, 175-91	7.9	8
45	A single dose of an effective whole cell pertussis vaccine does not significantly increase protection in children primed with a less effective vaccine. <i>Vaccine</i> , 1999 , 17, 448-53	4.1	
44	Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. <i>Journal of Pediatrics</i> , 1999 , 135, 240-5	3.6	9
43	Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. <i>Pediatrics</i> , 1999 , 104, 1-6	7.4	270
42	Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). <i>Clinical Infectious Diseases</i> , 1999 , 28, 1238-43	11.6	127
41	Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in <i>Streptococcus gordonii</i> . <i>Infection and Immunity</i> , 1999 , 67, 1511-6	3.7	31
40	Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. <i>Pediatric Infectious Disease Journal</i> , 1999 , 18, 505-11	3.4	55
39	Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. <i>Pediatric Infectious Disease Journal</i> , 1999 , 18, 772-9	3.4	41
38	Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. <i>Vaccine</i> , 1998 , 16, 1331-5	4.1	24
37	Pertussis epidemic and sudden infant death syndrome. <i>Clinical Pediatrics</i> , 1998 , 37, 449-51	1.2	2

36	Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 280, 1685-9	27.4	179
35	Current practices of adjunctive therapy for pertussis at six Canadian tertiary care pediatric hospitals. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1998 , 9, 83-6		
34	Comparison of parental and health care professional preferences for the acellular or whole cell pertussis vaccine. <i>Pediatric Infectious Disease Journal</i> , 1998 , 17, 103-9	3.4	13
33	Seven days of erythromycin estolate is as effective as fourteen days for the treatment of <i>Bordetella pertussis</i> infections. <i>Pediatrics</i> , 1997 , 100, 65-71	7.4	64
32	Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. <i>Journal of Pediatrics</i> , 1997 , 130, 525-31	3.6	21
31	Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. <i>Vaccine</i> , 1997 , 15, 301-6	4.1	48
30	Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with <i>Haemophilus influenzae b</i> conjugate vaccine. <i>Vaccine</i> , 1997 , 15, 295-300	4.1	15
29	Prevention of perinatal group B streptococcal infection: Management strategies. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1997 , 8, 68-70		4
28	Acellular pertussis vaccines: the next step. <i>Developments in Biological Standardization</i> , 1997 , 89, 363-5		2
27	Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. <i>Vaccine</i> , 1996 , 14, 767-72	4.1	35
26	Acellular pertussis vaccines have arrived. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1996 , 7, 359-60		1
25	Effect of inactivated poliovirus vaccine on the antibody response to <i>Bordetella pertussis</i> antigens when combined with diphtheria-pertussis-tetanus vaccine. <i>Clinical Infectious Diseases</i> , 1996 , 22, 59-62	11.6	21
24	Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. <i>Pediatric Infectious Disease Journal</i> , 1996 , 15, 519-24	3.4	31
23	Rapid diagnosis of pertussis using the Chinese hamster ovary cell cytotoxicity assay. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1995 , 14, 255-7	5.3	2
22	Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 279-87		16
21	Immune responses to pertussis vaccines concurrently administered with viral vaccines. <i>Annals of the New York Academy of Sciences</i> , 1995 , 754, 89-96	6.5	10
20	Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. <i>Pediatric Infectious Disease Journal</i> , 1995 , 14, 792-7	3.4	33
19	Clinical course of pertussis in immunized children. <i>Pediatric Infectious Disease Journal</i> , 1995 , 14, 870-4	3.4	28

18	A national consensus on prevention of early-onset group B streptococcal infection in the newborn. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1994 , 5, 250-1		1
17	Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. <i>JAMA Pediatrics</i> , 1994 , 148, 495-502		18
16	Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. <i>JAMA Pediatrics</i> , 1994 , 148, 1220-4		12
15	Identification of <i>Bordetella pertussis</i> infection by shared-primer PCR. <i>Journal of Clinical Microbiology</i> , 1994 , 32, 783-9	9.7	55
14	Deficient priming activity of newborn cord blood-derived polymorphonuclear neutrophilic granulocytes with lipopolysaccharide and tumor necrosis factor-alpha triggered with formyl-methionyl-leucyl-phenylalanine. <i>Pediatric Research</i> , 1993 , 34, 243-8	3.2	29
13	Changing pattern of clinical illness in children with group A streptococcal bacteremia. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1993 , 4, 341-6		1
12	Prolonged survival of <i>Bordetella pertussis</i> in a simple buffer after nasopharyngeal secretion aspiration. <i>Canadian Journal of Microbiology</i> , 1992 , 38, 1210-3	3.2	11
11	Antibody response to <i>Bordetella pertussis</i> antigens after immunization with American and Canadian whole-cell vaccines. <i>Journal of Pediatrics</i> , 1992 , 121, 523-7	3.6	55
10	Office diagnosis of pertussis. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1992 , 3, 221-2		
9	Modulation of <i>Bordetella pertussis</i> infection with monoclonal antibodies to pertussis toxin. <i>Journal of Infectious Diseases</i> , 1991 , 163, 355-61	7	51
8	Pertussis encephalopathy in an adult: case report and review. <i>Clinical Infectious Diseases</i> , 1991 , 13, 1043-1046		35
7	<i>Haemophilus influenzae</i> type B and its role in diseases of the head and neck. <i>The Journal of Otolaryngology</i> , 1990 , 19, 169-74		2
6	Use of a Chinese hamster ovary cell cytotoxicity assay for the rapid diagnosis of pertussis. <i>Journal of Clinical Microbiology</i> , 1990 , 28, 32-8	9.7	18
5	Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. <i>Journal of Pediatrics</i> , 1989 , 115, 686-93	3.6	73
4	Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. <i>Journal of Clinical Microbiology</i> , 1989 , 27, 752-7	9.7	62
3	Experimental respiratory infection with <i>Bordetella pertussis</i> in mice: comparison of two methods. <i>Clinical and Investigative Medicine</i> , 1988 , 11, 297-303	0.9	14
2	Exacerbations of asthma in adults during experimental rhinovirus infection. <i>The American Review of Respiratory Disease</i> , 1985 , 132, 976-80		64
1	Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. <i>The American Review of Respiratory Disease</i> , 1983 , 128, 806-10		65

